Mast cell tryptase is stored as an active tetramer in complex with heparin in mast cell secretory granules. Previously, we demonstrated the dependence on heparin for the activation/tetramer formation of a recombinant tryptase. Here we have investigated the structural requirements for this activation process. The ability of heparin-related saccharides to activate a recombinant murine tryptase, mouse mast cell protease-6 (mMCP-6), was strongly dependent on anionic charge density and size. The dose-response curve for heparin-induced mMCP-6 activation displayed a bell-shaped appearance, indicating that heparin acts by binding to more than one tryptase monomer simultaneously. The minimal heparin oligosaccharide required for binding to mMCP-6 was 8 -10 saccharide units. Gel filtration analyses showed that such short oligosaccharides were unable to generate tryptase tetramers, but instead gave rise to active mMCP-6 monomers. The active monomers were inhibited by bovine pancreatic trypsin inhibitor, whereas the tetramers were resistant. Furthermore, monomeric (but not tetrameric) mMCP-6 degraded fibronectin. Our results suggest a model for tryptase tetramer formation that involves bridging of tryptase monomers by heparin or other highly sulfated polysaccharides of sufficient chain length. Moreover, our results raise the possibility that some of the reported activities of tryptase may be related to active tryptase monomers that may be formed according to the mechanism described here.
released together with preformed mediators such as histamine, heparin proteoglycan, and various proteases from the secretory granules. The three major classes of mast cell proteases include tryptases (trypsin-like substrate specificity), chymases (chymotrypsin-like substrate specificity), and carboxypeptidase A (3, 4) . All mast cell proteases are stored in their active form, i.e. with their activation peptides removed. Earlier studies indicated that tryptase, in its active form, is a tetramer (5) . Recently, determination of the crystal structure of human ␤-tryptase clarified that the four active sites in the tryptase tetramer are facing a narrow central pore (6 -8) . This results in limited accessibility of the active sites to macromolecular compounds and explains the unusual resistance of tryptase to large protease inhibitors, e.g. those present in plasma (9) . Although several studies have identified tryptase as a potent pro-inflammatory mediator, its mechanism of action has not been defined, i.e. its in vivo target protein or peptide has not been identified (10 -14) . One possibility is that tryptase acts by cleaving proteinase-activated receptor-2, which is thereby activated (15) .
In the secretory vesicles, the active tryptases are associated with heparin proteoglycan. Heparin is a glycosaminoglycan composed of repeating disaccharide units of the general structure ((GlcUA/IdoUA)-GlcNAc) n . In its proteoglycan form, the heparin chains are attached to a serglycin protein core (16) . Structural diversity is introduced into the heparin chains by N-deacetylation/N-sulfation of GlcNAc residues and C-5 epimerization of glucuronic acid residues to iduronic acid, followed by C-2 O-sulfation of selected uronic acid residues as well as C-3 and C-6 O-sulfation of glucosamine residues (17) . Because of its high degree of sulfation, heparin displays a high negative charge density and is thus able to interact with the various positively charged compounds in the mast cell.
The association of tryptase with heparin has been shown to influence tryptase at various levels. First, it has been shown that heparin is essential to obtain proper storage of tryptase without affecting mRNA expression levels (18, 19) . Second, the association of tryptase with heparin is known to be required for stabilization of tryptase after exocytosis (20 -22) . In this context, it is noteworthy that heparin-binding compounds (e.g. polycations) are strongly inhibitory for mast cell tryptase, apparently by competing with tryptase for binding to heparin (23, 24) . It has also been suggested that the presence of heparin is required in the autocatalytic processing of protryptase to mature tryptase monomer (25) . Following cleavage of the activation peptide, tryptase monomers are assembled into tetramers and thereby acquire enzymatic activity. In a previous study, we investigated the possible role of heparin in tryptase tetramer-ization (10) . A recombinant mouse tryptase, mouse mast cell protease-6 (mMCP-6), 1 was expressed with an N-terminal His tag followed by an enterokinase cleavage site replacing the native activation peptide. Enterokinase cleavage of this fusion protein thus yielded the mature tryptase monomer. Using this recombinant tryptase, we showed that heparin is required for the assembly of monomeric inactive tryptase to active tetramers and that tetramerization only occurs at acidic pH (below ϳ6.5) (10). The strong pH dependence of the tetramerization process indicated that histidine residues, which are positively charged at pH Ͻ6.5, but uncharged at neutral pH, may be involved in the interaction with heparin.
In this study, we have investigated the mechanism and structural requirements (in terms of heparin) for the assembly of inactive tryptase monomers into active tetramers. Our results indicate that tryptase tetramerization involves bridging of tryptase monomers by heparin or similar highly sulfated polysaccharides of sufficient chain length. When heparin oligosaccharides of shorter length are used, active tryptase monomers are instead formed.
EXPERIMENTAL PROCEDURES
All studies were performed using mMCP-6. The expression, purification, and activation of mMCP-6 have been previously described (10) . Briefly, a mMCP-6 construct inserted in the pCEP-Pu2 vector was transfected into human 293 cells. This vector also contained the BM40 signal peptide, which ensures secretion of the protein into the culture medium. The recombinant protein was constructed with an N-terminal 6-histidine tag followed by an enterokinase (EK) cleavage site, which replaced the natural activation peptide. His 6 -EK-mMCP-6 was purified on Ni 2ϩ -nitrilotriacetic acid-agarose (QIAGEN GmbH, Hilden, Germany) according to instructions provided by the manufacturer. To obtain mature mMCP-6 monomers, the His 6 -EK-mMCP-6 fusion protein was digested overnight (37°C) with enterokinase at an enterokinase/mMCP-6 ratio of 1:500 (w/w) in PBS (10 mM phosphate, 0.14 M NaCl, and 2.7 mM KCl, pH 6). Active mMCP-6 was obtained after incubating the protein with heparin at pH 6 as described (10) (see also below). Unlabeled pig mucosal heparin (M r ϳ15,000), heparan sulfate from whale lung, dermatan sulfate, and 3 H-labeled heparin (25,000 cpm/g) were gifts from Ulf Lindahl (Uppsala University, Uppsala, Sweden). Heparin proteoglycan (M r ϳ1 ϫ 10 6 ) was purified from rat peritoneal mast cells as described previously (26) . Chondroitin sulfates A, C, and E were purchased from Calbiochem (Darmstadt, Germany). Dextran sulfate (M r ϳ8000) was obtained from Sigma. Unlabeled and 3 H-labeled heparin oligosaccharides (56,000 cpm/nmol) and the selectively desulfated heparin preparations (N-desulfated/N-acetylated heparin, 2-O-desulfated/N-sulfated heparin, 2-O-desulfated/N-desulfated heparin, and 6-O-desulfated heparin) were as described (27) (28) (29) . Enterokinase was from Roche Molecular Biochemicals (Mannheim, Germany). The chromogenic substrate S-2288 (H-D-Ile-Pro-Arg p-nitroanilide) was from Chromogenix (Mölndal, Sweden). Bovine pancreatic trypsin inhibitor (BPTI) was purchased from Sigma. SDS-polyacrylamide gel electrophoresis in a Laemmli system was performed with 12% polyacrylamide gels under nonreducing conditions. Gels were stained with Coomassie Blue.
Enzymatic Assays-Enzymatic assays were performed in 96-well microtiter plates. mMCP-6 (100 -200 ng) was incubated with different saccharides (445 pM to 44.5 M) in PBS (total volume of 130 -260 l), pH 6, for 30 min. In one set of experiments, the standard PBS buffer (0.14 M NaCl) was replaced by phosphate buffers containing 0 -0.5 M NaCl. Subsequently, mMCP-6 activity was recorded using a Titertek Multiscan spectrophotometer (Flow Laboratories) after addition of 20 l of a 2 mM solution of S-2288 in H 2 O.
Binding Assays-The binding of mMCP-6 to heparin was studied using the nitrocellulose filter disc assay of Pejler (30) were rapidly passed through prewashed (with PBS, pH 6) nitrocellulose filters (25-mm diameter, 0.45-m pore size; Sartorius Corp.) using a vacuum suction apparatus. Subsequently, the filters were washed with PBS, pH 6 (2 ϫ 5 ml), and transferred into scintillation vials. Bound radioactivity was eluted from the filters by addition of 2 ml of 100 mM NaOH and 2 M NaCl. After 30 min, 5 ml of scintillation fluid (OptiPhase HiPhase 3, Wallac) was added, and radioactivity was quantified with a ␤-scintillation counter.
Size-exclusion Gel Chromatography-Size-exclusion gel chromatography was performed in a fast protein liquid chromatography system (Amersham Pharmacia Biotech) using a Superdex 200 column (10 ϫ 300 mm). The column was equilibrated and eluted with PBS, pH 6, and run at a flow rate of 0.5 ml/min. Calibration was performed with the following standards (all from Sigma): carbonic anhydrase (29 kDa), bovine serum albumin (66 kDa), alcohol dehydrogenase (150 kDa), ␣-amylase (200 kDa), and blue dextran (2000 kDa). Enterokinase-digested His 6 -EK-mMCP-6 (10 -20 g, 0.33-0.66 nmol) was analyzed either alone or after preincubation with 3.3 nmol of either intact heparin or various heparin oligosaccharides of 20, 10, or 4 saccharide units. Absorbance was recorded at 280 nm. 0.5-ml fractions were collected from which 200-l samples were analyzed for tryptase activity after addition of 20 l of 2 mM S-2288. In the inhibition studies, 100 l of the fractions was transferred to 96-well plates and either not treated further or mixed with 2 g of protease inhibitor (BPTI, ␣ 1 -antitrypsin, soybean trypsin inhibitor) in 10 l of PBS. After an incubation time of 30 min, residual tryptase activity was determined as described above.
RESULTS

Structural Requirements for the Activation of mMCP-6 by
Heparin-In a previous study, we showed that the activation and tetramer formation of a recombinant tryptase, mMCP-6, is dependent on heparin and acidic pH (10) . In this study, we examined the mechanism and structural requirements for the heparin-induced tryptase activation. First, we investigated whether other structurally related saccharides were capable of replacing heparin as tryptase activators. Monomeric mMCP-6 was incubated with heparin, heparin proteoglycan, heparan sulfate, dermatan sulfate, chondroitin sulfate (A, C, or E), or dextran sulfate at increasing concentrations and was then assayed with the chromogenic substrate S-2288 for tryptase activity ( Fig. 1 ). As expected, both heparin and heparin proteoglycan produced active tryptase. In addition, dextran sulfate proved to be an effective tryptase activator. In fact, dextran sulfate was even more effective than heparin. In contrast, heparan sulfate, dermatan sulfate, and chondroitin sulfates A and C did not give any detectable activation of mMCP-6. Chondroitin sulfate E at high concentrations produced measurable tryptase activation, although the levels of activity were much lower than those obtained with heparin or dextran sulfate.
To investigate the heparin size requirements for mMCP-6 activation, we used heparin oligosaccharides of increasing chain lengths (4 -26 saccharide units). None of these oligosaccharides were as effective as intact heparin in production of active tryptase (Fig. 2) . However, clearly measurable levels of tryptase activity were seen after incubation with several of the various oligosaccharides, and an increased ability to activate mMCP-6 with increasing chain length was observed.
A possible explanation for the limited ability of the heparin oligosaccharides to produce active tryptase could be that shorter heparin chains require longer incubation times to achieve tryptase activation. To test this, we compared heparin and 20-unit saccharides at three different concentrations for their ability to activate mMCP-6 over time. The results shown in Fig. 3 demonstrate that the 20-unit saccharides gave a lower level of maximal activity compared with intact heparin, in agreement with the results shown in Fig. 2 . Furthermore, the maximal levels of activities were reached at equal rates both for the 20-unit saccharides and intact heparin.
Heparin contains sulfate groups at various positions: the uronic acid residues (both GlcUA and IdoUA) can be 2-Osulfated, and the glucosamine residues can carry 6-O-sulfate and/or N-sulfate groups. In addition, in rare cases, the glucosamine residues may contain 3-O-sulfate groups. To determine whether tryptase activation shows a requirement for sulfate groups located at any of these specific positions, we tested whether various chemically modified heparins were able to activate mMCP-6 (Fig. 4) . However, preferentially 2-O-desulfated, 6-O-desulfated, and N-desulfated heparins were approximately equally effective as activators of tryptase, indicating that none of the various sulfate groups are of critical importance. Although all of these modified heparins were capable of activating mMCP-6, none were as effective as intact heparin.
Effect of Sodium Chloride Concentration on the Activation of mMCP-6 -It has been reported previously (22, 31, 32) that high NaCl concentrations (ϳ1 M) stabilize the activity of human lung tryptase by preventing dissociation of the tryptase tetramer. Here we investigated whether also the mMCP-6 activation process was influenced by the concentration of NaCl. In contrast to the beneficial effect of high [NaCl] on tryptase stabilization, we found that mMCP-6 activation was most efficient at low NaCl concentrations, up to ϳ0.14 M (Fig. 5) . At higher NaCl concentrations, the possibility to obtain active tryptase after addition of heparin fell drastically, with complete inhibition of the activation process at NaCl concentrations above ϳ0.3 M (Fig. 5) .
Dependence on the Concentration of Heparin and mMCP-6 for Tryptase Activation-To investigate if tryptase activation is dependent on the concentrations of tryptase and heparin, three concentrations of mMCP-6 were incubated with increasing concentrations of heparin (Fig. 6) . The results show that the specific activity of mMCP-6 increased markedly with increasing mMCP-6 concentration. Furthermore, at all mMCP-6 concentrations, we noted bell-shaped dose-response curves for heparin, where the tryptase activity levels first reached a maximal plateau, but then decreased markedly at excess heparin concentrations (Fig. 6) .
Binding of mMCP-6 to Heparin-Binding studies were performed in which monomeric mMCP-6 was incubated with 3 Hlabeled heparin. Tryptase-bound radioactivity was then determined using the nitrocellulose filter disc assay (see "Experimental Procedures"). The same samples were also assayed for tryptase activity to directly correlate binding and activation (Fig. 7) . Saturation of the binding occurred at a heparin/tryptase ratio of ϳ1:1. However, the activity continued to increase at higher heparin concentrations than those required for maximal binding. Next, binding studies were performed in which 3 H-labeled oligosaccharides (4 -24 saccharide units) were incubated with mMCP-6, followed by the nitrocellulose filter disc assay. The results shown in Fig. 8 indicate that the minimal heparin chain size required for binding was 8 -10 saccharide units.
Formation of Active Tryptase Monomers-In a previous report, we showed that addition of intact heparin to mMCP-6 monomers results in the formation of active tetramers (10).
Here we used size-exclusion gel chromatography to study the effect of heparin oligosaccharides on mMCP-6 tetramerization. Mature monomeric mMCP-6 was incubated either alone or together with heparin 4-, 10-, or 20-unit saccharides or intact heparin and analyzed on a Superdex 200 column (Fig. 9) . In the absence of added heparin, no tetramer formation was seen, and no enzymatic activity was detected (Fig. 9A) . Addition of intact heparin transferred approximately half of the material into tetramers and resulted in generation of enzymatic activity, of which essentially all was found in the tetramer fraction (Fig.  9B) . Previous studies showed that if heparin is added at a larger molar excess, complete tetramerization is obtained (10) . Incubation of monomeric mMCP-6 with heparin 4-unit saccharides did not result in any detectable tetramerization or activation (Fig. 9C) . No tetramerization was obtained with the 10-unit saccharide. However, clearly detectable activity was found in the monomer peak after addition of heparin 10-unit saccharides to mMCP-6 (Fig. 9D) . Incubation of monomeric mMCP-6 with 20-unit saccharides produced a detectable tetramer peak (ϳ15% of the protein), although the majority of the protein eluted in the monomer fraction. Again, the monomer fractions displayed enzymatic activity. However, comparison of the height of the protein (A 280 ) and activity peaks indicated that the specific activity was considerably higher for the tryptase recovered in the tetramer fraction compared with the monomer fraction. To make sure that the activity found in the monomer fraction was due to monomers and not tetramers that had been assembled after the chromatography step, monomer fractions were pooled and rerun on the Superdex 200 column. Again, the activity was found in the monomer position (data not shown).
To obtain further proof for the formation of active monomers, we compared the susceptibility of the tetramer and monomer fractions of mMCP-6 to various protease inhibitors. Neither soybean trypsin inhibitor nor ␣ 1 -antitrypsin inhibited tryptase activities eluted in the tetramer or monomer fractions (data not shown). In contrast, BPTI inhibited the tryptase activity in the monomer (but not tetramer) fractions (Fig. 10) . Both the monomeric and tetrameric tryptases were inhibited by protamine, a polycationic heparin antagonist (data not shown).
Earlier studies have indicated that fibronectin is a substrate for tryptase (33, 34) . Further experiments were conducted to assess whether fibronectin is a substrate for both tetrameric and monomeric tryptases. Monomeric active tryptase was obtained after incubation of monomeric mMCP-6 with 20-unit saccharides, followed by separation of active tetramers and monomers by size-exclusion gel chromatography (Fig. 9E) . The results shown in Fig. 11 demonstrate that fibronectin was degraded by monomeric mMCP-6, but not by mMCP-6 in tetrameric form.
DISCUSSION
This study was undertaken to investigate the mechanism and structural requirements in the heparin-induced activation/ tetramerization of tryptase. Mature mouse tryptase monomers were obtained by enterokinase digestion of a fusion protein containing mature monomeric mMCP-6 expressed with an Nterminal His 6 tag followed by an enterokinase site replacing the natural activation peptide. The structural requirements in the activation of tryptase were studied by comparing the potency of heparin and various other structurally related compounds. Both intact heparin chains and heparin in its proteoglycan form were efficient activators. In contrast, heparan sulfate, dermatan sulfate, and chondroitin sulfates (A, C, and E) were not efficient tryptase activators. Since these compounds are all less sulfated than heparin, our results indicate that efficient tryptase activation requires binding of tryptase to highly sulfated compounds. It is interesting to note that, of these latter polysaccharides, only chondroitin sulfate E gave any detectable activation of mMCP-6. Chondroitin sulfate E has a higher sulfate content than both chondroitin sulfates A and C, in agreement with a dependence of tryptase activation on the high anionic charge of its ligand. Dextran sulfate, a synthetic polysaccharide with a high sulfate content, activated tryptase with an even higher efficiency than heparin. Since dextran sulfate has a carbohydrate backbone structure that differs drastically from that of heparin, this finding further supports that the major factor for tryptase activation is anionic charge density rather than more specific structural requirements. This was also supported by experiments with structurally modified heparins in which the N-sulfate, 2-O-sulfate, or 6-O-sulfate groups had been selectively removed. All of these modified heparins were approximately equally effective tryptase activators, suggesting that the interaction of tryptase with heparin is not dependent on sulfate groups at any particular position.
Heparin oligosaccharides composed of up to 26 monosaccharides were much less efficient in producing active tryptase than was intact heparin, indicating that tryptase activation is strongly size-dependent regarding heparin chain length. Studies were undertaken to investigate if the ability to activate tryptase is a direct function of tryptase-binding properties. Such experiments showed that oligosaccharides (e.g. 8 -10 saccharide units) that were relatively inefficient in producing tryptase activation could bind to tryptase. This raises the possibility that tryptase binding does not necessarily lead to tetramerization and activation. A possible explanation would be that tetramerization requires that at least two monomers are bound alongside the same heparin molecule, whereby heparin thus "bridges" these monomers to facilitate intermolecular contact (Fig. 12) . This would explain why heparin oligosaccharides of sufficient size for binding (e.g. 10 saccharide units) are relatively unable to cause efficient tryptase tetramerization. According to such a mechanism, bridging would require that at least two tryptase monomers interact with the same heparin molecule, i.e. forming a ternary complex. If this is the case, tryptase activation would be expected to be most efficient at heparin concentrations that are optimal for promoting formation of ternary complexes between heparin and at least two tryptase monomers. At higher heparin concentrations, there should be a reduced probability that monomers are bound to the same heparin chain since the excess of heparin should favor formation of binary complexes between heparin and solitary tryptase monomers. Indeed, our results illustrate that tryptase activation shows a bell-shaped dose-response curve, with reduced tryptase activation at excess heparin concentrations, in agreement with such a mechanism. It should be noted that similar bell-shaped dose-response curves have been observed in other processes in which heparin acts by bridging two heparinbinding protein molecules, e.g. the acceleration of antithrombin-mediated thrombin inactivation (35) and chymase-catalyzed thrombin degradation (36) .
When we compared the capability of heparin to bind to and activate tryptase, we observed that, although the binding was saturated at an ϳ1:1 molar ratio of heparin to tryptase monomer, tryptase activity continued to increase at higher heparin concentrations. In fact, optimal tryptase activation was seen at a molar ratio of ϳ200:1. The explanation for this apparent discrepancy is not certain. One possibility could be that tryptase contains both high and low affinity binding sites for heparin and, if this is the case, that optimal tryptase activation requires binding of heparin to both high and low affinity binding sites. Since the nitrocellulose filter disc assay we used for studying binding of heparin to tryptase involves a washing step, this assay represents a non-equilibrium system. The assay is therefore likely to detect high affinity interactions, whereas loosely bound heparin molecules may detach during the washing step and thus escape detection. In contrast, the equilibrium between heparin and tryptase is not disturbed in the activity assay. This assay should therefore allow detection of both high and low affinity interactions.
It is well established that high concentrations of NaCl stabilize human tryptase (22, 32) . A likely interpretation for this observation would be that hydrophobic interactions are important in tryptase tetramer stabilization. However, we have shown here that there is an opposite relation between NaCl concentration and ability to form active tryptase. Optimal tryptase activation occurred at NaCl concentrations up to ϳ0.14 M, whereas tryptase activation was completely abrogated at NaCl concentrations above ϳ0.3 M. Since NaCl would interfere with electrostatic interactions, but strengthen hydrophobic interactions, we conclude that electrostatic interactions are of higher importance than the hydrophobic counterparts during tryptase activation, at least during the initial phases of tetramer assembly. Once heparin has bound to tryptase, it is quite likely that additional hydrophobic interactions between different monomers contribute to stabilizing the tetramer structure, as indicated from the crystal structure of human tryptase (6) .
We have shown here, using size-exclusion gel chromatography, that short heparin oligosaccharides (e.g. 10 saccharide units) are capable of producing active tryptase monomers rather than tetramers. Further proof that the compounds present in the monomer position actually corresponded to active monomers (and not to tetramers that had been assembled after the chromatography step) came from inhibition studies in which BPTI was shown to inhibit tryptase in the monomer (but not tetramer) fraction. Resistance to macromolecular protease inhibitors is a classical feature of the mast cell tryptase tetramer (9) and is explained by its molecular organization, where the active sites that are located in the central pore are inaccessible to large protease inhibitors due to steric reasons (6, 7) . The access to the active site in an active monomer would obviously be less restricted, which would facilitate interaction with macromolecular protease inhibitors. The inhibition of the tryptase activity that was eluted from the Superdex 200 column in the position of monomers (but not tetramers) thus provides strong evidence that the active material eluting in the monomer fraction corresponds to true active tryptase monomers.
Tryptase has been reported to degrade several large pro- FIG. 11 . Degradation of fibronectin by mMCP-6 monomers. Enterokinase-digested His 6 -EK-mMCP-6 (17.4 g, 1.2 M) was incubated with 30 g of heparin 20-unit saccharide (11.6 M) in a total volume of 500 l of PBS, pH 6, followed by separation of tryptase tetramers and monomers (see Fig. 9E ). Fractions containing the highest tryptase activities were pooled, and 100 l of these samples was mixed with 60 g of fibronectin and incubated at 25°C. As a control, fibronectin was incubated in the absence of tryptase. Samples (25 l) from the tryptase/ fibronectin incubation mixtures were removed after 1, 4, and 20 h and subjected to SDS-polyacrylamide gel electrophoresis under nonreducing conditions.
teins, e.g. fibronectin, fibrinogen, and collagen type VI (33, 37) . However, as discussed in a recent review (8) , many of these proteins appear to be too large to fit into the central pore of the tryptase tetramer, thus questioning the relevance of many such findings. We have shown here, in accordance with such a notion, that fibronectin is not a substrate for tetrameric tryptase, but is readily degraded by monomeric active mMCP-6. These findings thus raise the possibility that at least some of the reported activities of tryptase toward macromolecular substrates may be due to small amounts of active monomers that are present in the tryptase preparations. However, the presence of active tryptase monomers in vivo remains to be investigated. Active monomers of human tryptase have been reported previously, although the mechanism for their formation was not studied, and functional differences between tetramers and monomers were not identified (22) . To our knowledge, this is the first report in which the existence of tryptase monomers, functionally distinct from the respective tetramers, is demonstrated. The mechanism for the formation of active tryptase monomers apparently involves interaction with heparin, similar to the generation of tetrameric tryptase. The continuous presence of heparin is known to be essential for maintaining the activity of tetrameric tryptase, and interfering with the interaction of tryptase with heparin leads to tetramer dissociation along with enzymatic inactivation (23) . A possible explanation for this would be that heparin is needed for bridging the tryptase subunits (see above and Fig. 12A ), although not necessarily affecting the actual active sites. Here we observed that also the monomeric active tryptase is inhibited by heparin antagonists and is thus dependent on the continuous presence of heparin for activity. The exact mechanism by which heparin activates the monomers is not clear, but may involve conformational changes that are induced upon heparin binding. When heparin is dissociated from the active tryptase monomer, its conformation could be distorted, which may lead to loss of enzymatic activity.
The formation of active monomers in the presence of short heparin oligosaccharides clearly supports the suggested mechanism for heparin-induced tryptase activation/tetramerization (Fig. 12) . Examination of the crystal structure for human ␤-tryptase revealed that a positively charged patch is present along two neighboring tryptase units in the tetramer and that this patch may accommodate a heparin chain of ϳ20 monosaccharides in length (6) . Possibly, this chain length corresponds to the minimal size required for the bridging of two tryptase monomers and thus for tetramerization. Accordingly, an oligosaccharide chain length of ϳ10 monosaccharide units would be expected to be required for interaction with each tryptase monomer. Oligosaccharides of this size should consequently be able to interact only with one tryptase molecule and would therefore be capable of producing active monomers only (Fig. 12) . Our results indicate that 8 -10 saccharide units indeed represent the minimal oligosaccharides required for tryptase binding, in close agreement with such a notion. Furthermore, our data indeed indicate that these smaller oligosaccharides are relatively unable to cause tetramerization, but instead preferentially promote formation of active monomers. In summary, we suggest a model for the formation of active tryptase tetramers in which tryptase monomers are bridged by heparin, or similar highly charged polysaccharides, of sufficient chain length (Fig. 12) . FIG. 12 . Model for heparin-induced tryptase activation. A, shown is the binding of tryptase monomers to intact heparin chains. The intact heparin allows binding of more than one tryptase monomer to the same heparin molecule (steps 1 and 2). If two tryptase monomers are bound adjacently (step 3), monomer-monomer interaction may be initiated along with subsequent tetramer assembly (step 4). In the model depicted, two heparin chains are bound to each tryptase tetramer. However, we cannot rule out that one heparin chain can accommodate all four subunits of the tetramer. B, interaction of tryptase monomers with heparin oligosaccharides that are not sufficiently long to accommodate two monomers may result in the formation of active monomers.
